STM2457, a new highly potent and selective first-in-class catalytic inhibitor of METTL3, has been proven to reverse the AML phenotype and prolong cell survival in various AML mouse models (Yankova et al., 2021). The gene discussed is METTL3; the disease is acute myeloid leukemia.